Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6694621 | 1.00 | SCN9A (0.49) | SCN9AGPR119PDE4BMMP13TACR1 | |
| SCHEMBL18345004 | 1.00 | SCN9A (0.49) | SCN9AGPR119PDE4BMMP13TACR1 | |
| SCHEMBL4436548 | 1.00 | SCN9A (0.49) | SCN9AGPR119PDE4BMMP13TACR1 | |
| SCHEMBL5459736 | 1.00 | SCN9A (0.49) | SCN9AGPR119PDE4BMMP13TACR1 | |
| SCHEMBL6689948 | 0.91 | SCN9A (0.48) | SCN9AGPR119PDE4BMMP13TACR1 | |
| SCHEMBL6689639 | 0.91 | SCN9A (0.48) | SCN9AGPR119PDE4BMMP13TACR1 | |
| SCHEMBL6689951 | 0.91 | SCN9A (0.48) | SCN9AGPR119PDE4BMMP13TACR1 | |
| SCHEMBL6848976 | 0.91 | SCN9A (0.48) | SCN9AGPR119PDE4BMMP13TACR1 | |
| SCHEMBL4710969 | 0.90 | TACR1 (0.49) | SCN9AGPR119PDE4BTACR1RORC | |
| SCHEMBL29450269 | 0.89 | STS (0.49) | SCN9AGPR119PDE4BMMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0812827-A1 | Piperidine derivative as intermediates for the preparation of paroxetine and process for their preparation | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 1997-12-17 | — | — | EP | claimed |
| EP-1966137-A2 | PIPERIDINE DERIVATIVES | Pfizer Products Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007072150-A2 | PIPERIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2007-06-28 | — | — | WO | disclosed |
| US-20070142389-A1 | PIPERIDINE DERIVATIVES | PFIZER INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-6815548-B2 | MINTERMEDIATE FOR PHARMACEUTICALS SUCH AS PAROXETINE USEFUL AS ANTIDEPRESSANTS, REPRESENTED BY THE GENERAL FORMULA (I): | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2004-11-09 | — | — | US | disclosed |
| EP-1394160-A1 | Process for preparing crystalline paroxetin hydrochloride | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
| EP-1384720-A1 | Process for drying paroxetine hydrochloride | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 2004-01-28 | — | — | EP | disclosed |
| EP-1384711-A1 | Optical resolution of a piperidine derivative | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 2004-01-28 | — | — | EP | disclosed |
| US-6610851-B1 | 1-tert-butoxycarbonyl-4-(4-fluorophenyl)-3-((3,4-methylene dioxyphenyl)oxymethyl)piperidine; reacting 4-(4-fluorophenyl)-3-hydroxymethylpiperidine with di-tert-butyl dicarbonate to form the carbamate; 3,4-methylenedioxyphenol | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2003-08-26 | — | — | US | disclosed |
| US-20030144519-A1 | Process for preparing a piperidine derivative | SUMIKA FINE CHEMICALS CO., LTD. | 2003-07-31 | — | — | US | disclosed |
| US-6476227-B1 | Piperidine derivative and process for preparing the same | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| US-5948914-A | PREPARING 4-(4-FLUOROPHENYL)-3-HYDROXYMETHYLPIPERIDINE BY OPTICALLY RESOLVING WITH O-CHLOROTARTRANILIC ACID; CHEMICAL INTERMEDIATE FOR DRUGS | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0812827-A1 | Piperidine derivative as intermediates for the preparation of paroxetine and process for their preparation | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 1997-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142389-A1 | PIPERIDINE DERIVATIVES | CFTR, HDAC10, RPP30 | SCN9A 1243/4885GPR119 216/4885PDE4B 975/4885 |
| US-20030144519-A1 | Process for preparing a piperidine derivative | TPH1, TPH2, HTR7 | SCN9A 1539/4885GPR119 1859/4885PDE4B 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.